Status: Recruiting
XTX301 in Patients With Advanced Solid Tumors
This is a first-in-human, multicenter, Phase 1/2, open-label study designed to evaluate the safety and tolerability of XTX301 as monotherapy in patients with advanced solid tumors.
Participants needed: 358
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Xilio Development, Inc.Updated: Jun 23, 2026Locations: 12
Eligibility criteria
ECOG performance status of 0-2 for Phase 1 [+4]
Prior treatment with IL-12 therapy (any form, e.g. recombinant human, prodrug, i... [+9]